H4 Orphan Pharma is a French pharmaceutical company founded in 2016 that is revolutionising the therapeutic approach
to fibrotic diseases.
H4 Orphan Pharma is developing two drug candidates with strong global commercial potential targeting orphan diseases: idiopathic pulmonary fibrosis and dry eye, in particular Gougerot-Sjögren’s syndrome.